What happened
- A team of 31 researchers, led by the Indian company Strand Life Sciences, published on 3 November 2026 in PNAS a study on circulating cell-free DNA and the detection of several cancer types with a blood test.
- It included 1,480 previously untreated people in 43 hospitals: patients with 14 cancer types at all stages, people with benign growths and healthy volunteers.
- People with cancer carry more cell-free DNA fragments in their blood. Most of that excess comes from immune cells, not the tumour, so it was expected to dilute the tumour signal.
- The study found the opposite: as total cell-free DNA rises, the share of fragments carrying cancer-associated methylation patterns increases.
Why it matters
- The finding held after accounting for cancer type, stage and a broad set of demographic, clinical and technical variables.
- Total cell-free DNA explains more variation in the tumour methylation signal than disease stage itself.
- It has a practical consequence: more cell-free DNA means higher sensitivity for detecting cancer, even within the same stage and especially at early stages.
The number
55% to 85%. That is how stage I cancer detection sensitivity varied between the third of patients with the lowest cell-free DNA and the third with the highest. At stage II it went from 59% to 86%.
Context
DNA methylation is a chemical mark that regulates which genes are expressed. Tumours have their own methylation patterns, and several multi-cancer detection tests look for those patterns in DNA circulating in the blood. The authors suggest the result reveals a coupling between immune cell activity and tumour methylation.
They therefore propose using cell-free DNA concentration as a stratification variable, independent of stage, when comparing cancer detection tests. Two tests evaluated in groups with different amounts of cell-free DNA could look different for that reason alone. A striking detail: patients with symptomatic benign lesions showed similar behaviour, suggesting a broader biological response to abnormal tissue growth rather than something unique to cancer.
At Mamífero we follow cancer research. We reported that a KRAS vaccine for pancreatic cancer missed its primary goal, that modified transfer RNAs repair the p53 gene and shrink tumours and that an antibody that activates two groups of T cells achieved responses in cold tumours. In neurology, Alzheimer-like changes in 14% of ALS patients were linked to shorter survival.
What’s next
- Makers of multi-cancer detection tests could report their results by cell-free DNA tertile.
- The signal in benign lesions means the number of false positives this effect generates needs study.
- The mechanism linking immune cells and tumour methylation remains to be explained.
Bottom line
What looked like noise turned out to be signal. More cell-free DNA in the blood does not hide the tumour; it makes it more visible, and that changes how early cancer detection tests should be compared.
Sources
- Basu, S., Hiremath, P., Rathod, N. et al., “Rising cell-free DNA level tracks cancer-associated methylation signal and improves multicancer detection”, PNAS, 3 November 2026, DOI 10.1073/pnas.2629041123. This note is based on the paper’s abstract.
- Cover image: Dotodot, CC BY-SA 4.0, via Wikimedia Commons
Edited by Rodrigo Cornejo. How we select and verify: who writes these notes.
